Literature DB >> 11137236

Infant and adolescent hepatitis B immunization up to 1999: a global overview.

R E Vryheid, M A Kane, N Muller, G C Schatz, S Bezabeh.   

Abstract

This article presents a global overview of hepatitis B infant and adolescent immunization programmes. The 108 reported universal infant or adolescent immunization programmes and 87 reported national infant coverage rates fit a pattern, explained by hepatitis B endemicity, prosperity, policy emphasis, and immunization programme strength. Most East and Southeast Asian, Pacific, and Middle Eastern countries have intermediate to highly endemic hepatitis B. Most have achieved 65-100% coverage. South and Central Asia and sub-Saharan Africa have intermediate to high endemicity, with some countries having hepatitis B immunization programmes. Some Southern and Eastern European countries, with intermediate endemicity, have high coverage. Low endemic Northern European countries vaccinate higher risk groups; some have universal infant or adolescent programmes. Caribbean and Latin American countries have varying endemicity, and most started programmes. Low endemic North American countries have universal vaccination programmes. Universal immunization strategies have greatly reduced incidence and prevalence, and are cost-effective for many countries, but many have difficulties affording this vaccine. Globally, most infants are not being immunized against hepatitis B virus infection. Increasing coverage, and decreasing the numbers of people diseased and dying from this virus, may require delivering heat-stable vaccine beyond cold chains, creative financing to reduce prices, and multivalent vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137236     DOI: 10.1016/s0264-410x(00)00239-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 2.  Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance.

Authors:  K Van Herck; E Leuridan; P Van Damme
Journal:  Sex Transm Infect       Date:  2007-10       Impact factor: 3.519

3.  Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Authors:  Vladimir Gilca; Gaston De Serres; Nicole Boulianne; Donald Murphy; Manale Ouakki; Phillipe De Wals; Gisele Trudeau; Richard Massé; Marc Dionne
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

4.  Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.

Authors:  Geert Leroux-Roels; Edwige Haelterman; Cathy Maes; Jack Levy; Fien De Boever; Laurent Licini; Marie-Pierre David; Kurt Dobbelaere; Dominique Descamps
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

5.  Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem (®) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine.

Authors:  Sanet Aspinall; Deirdre Traynor; Philip Bedford; Katharina Hartmann
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

6.  Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Paul J Cote; Brent E Korba; Scott D Butler; Andrea L George; Ilia A Tochkov; William E Delaney; Shelly Xiong; John L Gerin; Bud C Tennant
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Scott D Butler; Andrea L George; Ilia A Tochkov; Yuao Zhu; Shelly Xiong; John L Gerin; Paul J Cote; Bud C Tennant
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 8.  Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.

Authors:  David L Murdoch; Karen Goa; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.

Authors:  Stephan Menne; Bud C Tennant; John L Gerin; Paul J Cote
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.